Published in Ann Med on January 01, 2003
Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect. Atherosclerosis (2011) 1.59
Mechanisms of membrane binding of small GTPase K-Ras4B farnesylated hypervariable region. J Biol Chem (2015) 1.08
Unprenylated RhoA contributes to IL-1β hypersecretion in mevalonate kinase deficiency model through stimulation of Rac1 activity. J Biol Chem (2014) 1.07
Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels. Acta Pharmacol Sin (2010) 1.05
Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. Atherosclerosis (2009) 0.91
Differential metabolic actions of specific statins: clinical and therapeutic considerations. Antioxid Redox Signal (2013) 0.83
Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions. Sci Rep (2015) 0.81
Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. Front Aging Neurosci (2014) 0.80
Novel role of NADPH oxidase in ischemic myocardium: a study with Nox2 knockout mice. Funct Integr Genomics (2011) 0.78
Caveolin contributes to the modulation of basal and β-adrenoceptor stimulated function of the adult rat ventricular myocyte by simvastatin: a novel pleiotropic effect. PLoS One (2014) 0.76
Simvastatin inhibits sphingosylphosphorylcholine-induced differentiation of human mesenchymal stem cells into smooth muscle cells. Exp Mol Med (2012) 0.76
Should a statin be prescribed to every patient with heart failure? Heart Fail Rev (2007) 0.76
Original Research: Atorvastatin prevents rat cardiomyocyte hypertrophy induced by parathyroid hormone 1-34 associated with the Ras-ERK signaling. Exp Biol Med (Maywood) (2016) 0.75
Simvastatin Promotes Cardiac Myocyte Relaxation in Association with Phosphorylation of Troponin I. Front Pharmacol (2017) 0.75
Effect of Atorvastatin and Pioglitazone on Plasma Levels of Adhesion Molecules in Non-Diabetic Patients With Hypertension or Stable Angina or Both. J Clin Med Res (2015) 0.75
Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging. J Mol Cell Cardiol (2016) 0.75
The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell (1992) 28.36
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
Rho GTPases and the actin cytoskeleton. Science (1998) 28.19
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Rho GTPases and signaling networks. Genes Dev (1997) 11.70
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res (1994) 8.57
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med (2001) 7.51
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation (1998) 5.11
Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr Opin Cell Biol (1997) 4.72
Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem (1998) 3.97
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med (1995) 3.60
Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation (1997) 2.80
Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension (1998) 2.70
Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation (2002) 2.57
Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem (1995) 2.27
Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation (2001) 2.23
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest (2001) 2.19
Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem (1997) 2.12
Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation (2001) 2.04
Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest (1996) 1.86
Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J Clin Invest (1999) 1.82
Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem (1999) 1.73
MAP kinase- and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. EMBO J (1997) 1.66
Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J (1998) 1.65
Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest (2000) 1.58
Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem (1996) 1.57
Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol (2001) 1.51
The mitogen-activated protein kinase kinase MEK1 stimulates a pattern of gene expression typical of the hypertrophic phenotype in rat ventricular cardiomyocytes. J Biol Chem (1995) 1.50
Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem (1996) 1.48
Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation (2001) 1.47
The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. J Biol Chem (1998) 1.40
Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation (1997) 1.38
Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet (1996) 1.34
The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. J Am Coll Cardiol (2002) 1.28
A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. J Clin Invest (1998) 1.27
Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res (1995) 1.24
Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation (1998) 1.20
Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol (1999) 1.17
Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension (2002) 1.16
Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation (2002) 1.06
Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation (2001) 1.03
Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes. J Biol Chem (1998) 0.97
Studies on the function of rho A protein in cardiac myofibrillogenesis. J Cell Biochem (1997) 0.95
Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. Am J Physiol Heart Circ Physiol (2001) 0.94
Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation (2008) 3.48
Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol (2004) 3.18
Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med (2002) 3.17
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med (2008) 2.68
Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol (2006) 2.61
Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res (2002) 2.53
Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol (2003) 2.39
Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation (2002) 2.39
Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation (2003) 2.30
Essential role of endothelial Notch1 in angiogenesis. Circulation (2005) 2.28
Rho GTPases, statins, and nitric oxide. Circ Res (2005) 2.21
Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J (2010) 2.13
Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke (2005) 2.13
Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation (2005) 2.09
Ventricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/Hey2. Proc Natl Acad Sci U S A (2002) 2.04
Regulation of endothelial nitric oxide synthase and postnatal angiogenesis by Rac1. Circ Res (2008) 2.04
Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A (2006) 2.02
ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest (2008) 1.92
Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res (2006) 1.91
Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys (2005) 1.91
Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res (2006) 1.84
Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci U S A (2006) 1.79
NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol (2003) 1.75
Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol (2003) 1.75
Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation (2004) 1.73
RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J (2010) 1.67
Long-term statin use and psychological well-being. J Am Coll Cardiol (2003) 1.66
FHL2/SLIM3 decreases cardiomyocyte survival by inhibitory interaction with sphingosine kinase-1. Circ Res (2006) 1.63
Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol (2010) 1.62
Targeting eNOS for stroke protection. Trends Neurosci (2004) 1.60
Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res (2003) 1.59
Smooth muscle Notch1 mediates neointimal formation after vascular injury. Circulation (2009) 1.58
Increased Rho kinase activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol (2007) 1.46
Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation (2005) 1.45
Noninvasive method for assessing the human circadian clock using hair follicle cells. Proc Natl Acad Sci U S A (2010) 1.43
Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal (2009) 1.43
Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice. FASEB J (2008) 1.41
Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol (2002) 1.41
Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest (2010) 1.40
Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids. J Clin Invest (2002) 1.40
Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation (2007) 1.39
11,12-epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression. Bioorg Med Chem Lett (2003) 1.38
Increased vascular senescence and impaired endothelial progenitor cell function mediated by mutation of circadian gene Per2. Circulation (2008) 1.36
NF-κB and innate immunity in ischemic stroke. Ann N Y Acad Sci (2010) 1.34
Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol (2007) 1.33
Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J Cereb Blood Flow Metab (2006) 1.32
Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. J Clin Invest (2006) 1.31
Linking Notch signaling to ischemic stroke. Proc Natl Acad Sci U S A (2008) 1.28
A mouse model of diet-induced obesity and insulin resistance. Methods Mol Biol (2012) 1.27
A method for measuring Rho kinase activity in tissues and cells. Methods Enzymol (2008) 1.27
ROCKs as therapeutic targets in cardiovascular diseases. Expert Rev Cardiovasc Ther (2005) 1.25
Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today (2010) 1.24
Tumor necrosis factor-alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-alpha 1. Circ Res (2008) 1.24
1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res (2002) 1.20
Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol (2003) 1.19
Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis (2008) 1.19
Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr Pharm Des (2004) 1.19
Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab (2005) 1.18
Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci (2011) 1.17
Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol (2003) 1.14
Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation (2002) 1.11
Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep (2003) 1.11
Distribution of sphingosine kinase activity and mRNA in rodent brain. J Neurochem (2007) 1.11
Transcription factor CHF1/Hey2 suppresses cardiac hypertrophy through an inhibitory interaction with GATA4. Am J Physiol Heart Circ Physiol (2006) 1.10
Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol (2008) 1.09
Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des (2009) 1.09
Nonnuclear actions of estrogen. Arterioscler Thromb Vasc Biol (2002) 1.08
Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion. PLoS One (2012) 1.08
Notch1 in bone marrow-derived cells mediates cardiac repair after myocardial infarction. Circulation (2011) 1.06
Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res (2004) 1.05
Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des (2009) 1.04
Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg (2004) 1.03
Functional interaction of endothelial nitric oxide synthase with a voltage-dependent anion channel. Proc Natl Acad Sci U S A (2002) 1.03
Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol (2006) 1.02
Notch signaling regulates endothelial progenitor cell activity during recovery from arterial injury in hypercholesterolemic mice. Circulation (2010) 1.02
Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol (2004) 1.01
Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. J Cereb Blood Flow Metab (2008) 1.00
Rho-associated kinase activity, endothelial function, and cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2011) 1.00
Identification of ROCK1 as an upstream activator of the JIP-3 to JNK signaling axis in response to UVB damage. Sci Signal (2008) 0.99
Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. Atherosclerosis (2010) 0.99
Absence of TRAM restricts Toll-like receptor 4 signaling in vascular endothelial cells to the MyD88 pathway. Circ Res (2006) 0.98
Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase. Steroids (2002) 0.98
gamma-Secretase inhibitor reduces diet-induced atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun (2009) 0.98
Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. Biochem Pharmacol (2006) 0.96
Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid Redox Signal (2013) 0.96
FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB J (2012) 0.95
Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. Curr Opin Pharmacol (2010) 0.95
Drug Insight: statins and stroke. Nat Clin Pract Cardiovasc Med (2005) 0.94
Rho-associated coiled-coil-containing kinase 2 deficiency in bone marrow-derived cells leads to increased cholesterol efflux and decreased atherosclerosis. Circulation (2012) 0.93
Nontranscriptional actions of the glucocorticoid receptor. J Mol Med (Berl) (2003) 0.92
Increased leukocyte rho kinase (ROCK) activity and endothelial dysfunction in cigarette smokers. Hypertens Res (2010) 0.92
Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. J Hypertens (2011) 0.91
Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol (2008) 0.90
Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res (2008) 0.90
Vascular protection by estrogen in ischemia-reperfusion injury requires endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol (2002) 0.89
Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis. Hum Mol Genet (2011) 0.89
Rapid effects of statins: from prophylaxis to therapy for ischemic stroke. Arterioscler Thromb Vasc Biol (2003) 0.88
Notch signaling as an important mediator of cardiac repair and regeneration after myocardial infarction. Trends Cardiovasc Med (2010) 0.88
Pitavastatin-induced angiogenesis and arteriogenesis is mediated by Notch1 in a murine hindlimb ischemia model without induction of VEGF. Lab Invest (2011) 0.87